Dry Eye Syndrome Clinical Trial
Official title:
Expression of CXCL9, CXCL10, CXCL11, and CXCR3 in the Tear Film and Ocular Surface of Patients With Dry Eye Syndrome
Verified date | October 2009 |
Source | Chonnam National University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Korea: Institutional Review Board |
Study type | Observational |
The aim of this study is to investigate the expression of CXCL9, CXCL10, CXCL11, and CXCR3
in the tear film and ocular surface of patients with dry eye syndrome.
Thirty-three patients with dry eye (16 Sjögren's syndrome and 17 non-Sjögren's syndrome
patients) and 15 control subjects were recruited. The concentrations of CXCL9, CXCL10, and
CXCL11 in tears were measured using enzyme-linked immunosorbent assay. The correlation
between chemokine levels and tear film and ocular surface parameters was analyzed.
Expression of CXCL9, CXCL10, CXCL11, and CXCR3 in the conjunctiva was evaluated using
immunohistochemistry. Flow cytometry was performed to count CXCR3+ cells and CXCR3+CD4+
cells in the conjunctiva.
Status | Completed |
Enrollment | 48 |
Est. completion date | December 2008 |
Est. primary completion date | October 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 24 Years to 77 Years |
Eligibility |
Inclusion Criteria: - clinical diagnosis of dry eye syndrome Exclusion Criteria: - active ocular infection or inflammation not associated with dry eye - drug toxicity - contact lens wear - ocular allergy - ocular surgery within the last 3 months - lid or lash abnormalities |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Chonnam National University Hospital | Gwangju | Chonnam |
Lead Sponsor | Collaborator |
---|---|
Chonnam National University Hospital |
Korea, Republic of,
Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999 Sep;19(3):201-11. — View Citation
Wallace GR, John Curnow S, Wloka K, Salmon M, Murray PI. The role of chemokines and their receptors in ocular disease. Prog Retin Eye Res. 2004 Jul;23(4):435-48. Review. — View Citation
Yoon KC, De Paiva CS, Qi H, Chen Z, Farley WJ, Li DQ, Pflugfelder SC. Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress. Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2561-9. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02522312 -
A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients
|
N/A | |
Completed |
NCT02597803 -
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
|
Phase 2/Phase 3 | |
Completed |
NCT01863368 -
Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining
|
N/A | |
Completed |
NCT01753752 -
Evaluation of the Corneal Residence Time of Chitosan-N-acetylcysteine Eye Drops in Patients With Dry Eye Syndrome After Single and Multiple Instillation
|
Phase 2 | |
Completed |
NCT01753687 -
Correlation of Different Signs for Assessment of Dry Eye Syndrome
|
N/A | |
Completed |
NCT01198782 -
Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%
|
Phase 4 | |
Completed |
NCT01212471 -
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
|
Phase 3 | |
Completed |
NCT01162954 -
Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00544713 -
Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery
|
N/A | |
Completed |
NCT00535054 -
Study to Assess the Safety and Patients' Satisfaction of Tears Again* in the Treatment of Dry Eye Symptoms
|
N/A | |
Completed |
NCT00344721 -
A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome
|
N/A | |
Completed |
NCT03830359 -
Efficacy, Safety of T2769 in Dry Eye Disease
|
N/A | |
Completed |
NCT04139122 -
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02758327 -
Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops
|
Phase 4 | |
Completed |
NCT01970917 -
Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects
|
Phase 4 | |
Completed |
NCT02066051 -
IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
|
N/A | |
Completed |
NCT02092207 -
Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome
|
Phase 2 | |
Completed |
NCT01541891 -
Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome
|
Phase 2 | |
Completed |
NCT01252121 -
Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline
|
N/A | |
Completed |
NCT00765804 -
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye
|
Phase 2 |